Report: Optimizing Outsourcing in Early Small Molecule Drug Discovery

ACS report optimizing outsourcing drug discovery cover thumbnail

First name

Last name

Company name

Job title

Country

Yes, I would like to receive updates from Dotmatics on events and news. I may unsubscribe at any time.

Extra

Explore Trends and Needs in Biotech-CRO Collaborations

Outsourcing to contract research organizations (CROs) has been a strategic way for research companies to navigate a number of obstacles, including rising costs, waning funding options, and growing layoffs. There has been limited exploration of how to optimize early-discovery engagements, so Dotmatics commissioned C&EN BrandLab to survey Chemical & Engineering News readers about outsourced small-molecule-drug-discovery projects.

Survey Results

Biotechs are increasingly turning to multiple CROs for help in additional areas, such as drug metabolism and pharmacokinetic studies, as well as toxicology and safety assessment and more. Survey results also highlight the need to optimize biotech-CRO collaboration, with both bio-company and service-provider respondents citing a need for data-management solutions.

Read the full report to discover all of the insights from the survey, so you can put learnings into practice now.